TO WHAT EXTENT ARE BASELINE CHARACTERISTICS IN BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AT WEEK 24 OF GUSELKUMAB TREATMENT: A POST HOC ANALYSIS OF THE PHASE IIIB COSMOS CLINICAL TRIAL

被引：0
|
作者：
Tillett, W. [1 ]
Ohrndorf, S. [2 ]
Ramirez, J. [3 ]
Neuhold, M. [4 ]
Wapenaar, R. [5 ]
Theander, E. [6 ]
Contre, C. [7 ]
Sharaf, M. [8 ]
Shawi, M. [9 ]
Vis, M. [10 ]
机构：
[1] Univ Bath, Royal Natl Hosp Rheumat Dis, Bath, Avon, England
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Hosp Univ Clin, Barcelona, Spain
[4] Janssen Cilag, Zug, Switzerland
[5] Janssen Cilag BV, Breda, Netherlands
[6] Janssen Cilag, Solna, Sweden
[7] Janssen Cilag, Issy Les Moulineaux, France
[8] Janssen Cilag, Dubai, U Arab Emirates
[9] Janssen Global Serv LLC, Horsham, PA USA
[10] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2624
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1051
引用
收藏
页码：844 / 845
页数：2
相关论文
共 27 条
  • [1] TO WHAT EXTENT ARE BASELINE CHARACTERISTICS IN BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AT WEEK 24 OF GUSELKUMAB TREATMENT: A POST HOC ANALYSIS OF THE PHASE IIIB COSMOS CLINICAL TRIAL
    Tillett, William
    Ohrndorf, Sarah
    Ramirez, Julio
    Neuhold, Marlies
    Wapenaar, Robert
    Theander, Elke
    Contre, Christine
    Sharaf, Mohamed
    Shawi, May
    Vis, Marijn
    RHEUMATOLOGY, 2022, 61
  • [2] To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naive Patient Population
    Vis, Marijn
    Richette, Pascal
    Julio, Ramirez
    Neuhold, Marlies
    Wapenaar, Robert
    Theander, Elke
    Noel, Wim
    Shawi, May
    Kollmeier, Alexa
    Tillett, William
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3833 - 3836
  • [3] Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
    Ogdie, Alexis
    Mease, Philip
    Nantel, Francois
    Lavie, Frederic
    Sharaf, Mohamed
    Rampakakis, Emmanouil
    Marzo-Ortega, Helena
    Gossec, Laure
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1184 - 1187
  • [4] Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
    Mease, Philip
    Gottlieb, Alice
    McInnes, Iain
    Shiff, Natalie J.
    Todd, Anthony
    Rampakakis, Emmanouil
    Nantel, Francois
    Parrett, Jenna
    Lavie, Frederic
    Rahman, Proton
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2993 - 2996
  • [5] TRENDS IN CLINICAL CHARACTERISTICS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY IN RESPONSE TO BIOLOGIC THERAPY IN PSORIATIC ARTHRITIS - ANALYSES FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
    Mease, P. J.
    Karki, C.
    Liu, M.
    Kavanaugh, A.
    Ritchlin, C. T.
    Hunyh, D. H.
    Pandurengan, R.
    Palmer, J. B.
    Greenberg, J. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 953 - 953
  • [6] Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies
    Schneeberger, Emilce E.
    Citera, Gustavo
    Nash, Peter
    Smolen, Josef S.
    Mease, Philip J.
    Soriano, Enrique R.
    Helling, Claudia
    Szumski, Annette E.
    Mundayat, Rajiv
    de Leon, Dario Ponce
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 58
  • [7] Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
    Mcinnes, Iain B.
    Sewerin, Philipp
    Sharaf, Mohamed
    Efficace, Michela
    Lavie, Frederic
    Zimmermann, Miriam
    Coates, Laura C.
    RMD OPEN, 2024, 10 (04):
  • [8] IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NONRESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES
    Mcgonagle, D.
    Haaland, D.
    Helliwell, P.
    Marrache, M.
    Shawi, M.
    Rampakakis, E.
    Nash, P.
    Irazoque-Palazuelos, F.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1772 - 1773
  • [9] COMPARISON OF CLINICAL AND RADIOLOGIC TREATMENT OUTCOMES FOR PATIENTS WITH MODERATE VS. SEVERE PSORIATIC ARTHRITIS DISEASE ACTIVITY AT BASELINE: POST-HOC ANALYSIS OF ADEPT
    Mease, P. J.
    Kavanaugh, A.
    Perdok, R.
    Kupper, H.
    Lavie, F.
    RHEUMATOLOGY, 2010, 49 : I51 - I51
  • [10] STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY
    Ritchlin, C. T.
    Mease, P. J.
    Boehncke, W. H.
    Tesser, J.
    Chakravarty, S. D.
    Rampakakis, E.
    Shawi, M.
    Schiopu, E.
    Merola, J. F.
    Mcinnes, I.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1779 - 1780
123